TDP1 Antibody

What is TDP1 and what role does it play in cellular processes?

TDP1 (Tyrosyl-DNA phosphodiesterase 1) is an enzyme that hydrolyzes phosphodiester bonds between tyrosine and the 3'-phosphate of DNA. It plays multiple critical roles in DNA repair pathways:

• Repairs topoisomerase I-mediated cleavage complexes (Top1cc) by hydrolyzing 3′-phosphotyrosyl DNA bonds

• Processes other 3′ DNA end blocking lesions including 3′ abasic sites and 3′ phosphoglycolate

• Possesses limited DNA and RNA 3′ exonuclease activity that removes single nucleosides from 3′-hydroxyl ends

• Repairs both replication- and transcription-dependent DNA damage

• Facilitates double-strand break repair by removing glycolate from single-stranded DNA containing 3′-phosphoglycolate

TDP1 contains a unique HKD signature motif characterizing it as a member of the phospholipase D superfamily . Mutations in TDP1, particularly the H493R mutation, are associated with spinocerebellar ataxia with axonal neuropathy (SCAN1), a neurological disorder resulting from disrupted DNA transcription and neuronal apoptosis .

What types of TDP1 antibodies are available for research applications?

Several types of TDP1 antibodies are available for different research applications:

For molecular weight detection, TDP1 has a calculated molecular weight of 34 kDa and 68 kDa, but the observed molecular weight is typically 68 kDa in Western blotting applications . When selecting a TDP1 antibody, consider the specific application needs, target epitope, and compatible detection systems for your experimental design.

How are TDP1 antibodies used to study DNA repair mechanisms?

TDP1 antibodies provide valuable tools for investigating various aspects of DNA repair mechanisms:

• Monitoring TDP1 recruitment to DNA damage sites:

  • Immunofluorescence microscopy to visualize TDP1 foci formation after DNA damage

  • Co-localization studies with γH2AX (marker for DNA double-strand breaks) and XRCC1

  • Analysis of DNA damage-dependent TDP1 phosphorylation at S81 using phospho-specific antibodies

• Investigating TDP1 interactions with other repair proteins:

  • Co-immunoprecipitation experiments reveal TDP1 interactions with NHEJ factors like XLF and Ku70/80

  • TDP1 has been shown to promote assembly of non-homologous end joining protein complexes

  • Multiprotein:DNA complexes can be detected using TDP1 antibodies

• Quantifying repair activity in cellular contexts:

  • Tracking TDP1 expression levels in relation to DNA repair capacity

  • TDP1-deficient cells accumulate very high levels of SSBs (single-strand breaks) and DSBs (double-strand breaks) after treatment with camptothecin

  • TDP1 deficiency promotes accumulation of topoisomerase I-DNA complexes (TOP1cc)

• Distinguishing repair pathway activation:

  • TDP1 phosphorylation is induced by both replication- and transcription-coupled DNA damage

  • Using cell cycle inhibitors (aphidicolin) and transcription inhibitors (DRB) reveals pathway-specific activation patterns

  • Studies in non-replicating cells (primary lymphocytes) confirm transcription-dependent TDP1 activation

These antibody-based approaches have revealed that TDP1 functions in multiple DNA repair pathways, extending beyond its classical role in TOP1cc resolution to include broader participation in single and double-strand break repair.

What are the optimal conditions for detecting TDP1 using Western blotting?

For optimal TDP1 detection by Western blotting, the following conditions are recommended:

For phospho-specific TDP1 antibodies (e.g., pS81-TDP1), additional considerations include:

• Include phosphatase inhibitors in lysis buffer

• Use cells treated with DNA damaging agents (e.g., CPT, ionizing radiation) as positive controls

• Include phosphatase-treated samples as negative controls

• For mutant validation, use cells expressing TDP1 variants (S81A, S365A, S563A)

The observed molecular weight of TDP1 is typically 68 kDa, though calculated molecular weights include both 34 kDa and 68 kDa forms . Knockdown validation using siRNA against TDP1 is strongly recommended to confirm antibody specificity .

How can phospho-specific TDP1 antibodies illuminate DNA damage response pathways?

Phospho-specific TDP1 antibodies, particularly those targeting pS81-TDP1, provide powerful insights into DNA damage response mechanisms:

• Kinase pathway activation detection:

  • pS81-TDP1 antibodies detect ATM-dependent phosphorylation of TDP1 following DNA damage

  • In vitro kinase assays with ATM and DNA-PK identified ATM as the primary kinase responsible for S81 phosphorylation

  • This phosphorylation specifically occurs at serine-glutamine (SQ) motifs, ATM's preferred target sites

• Spatiotemporal dynamics of DNA damage response:

  • Immunofluorescence with pS81-TDP1 antibodies reveals distinct nuclear foci formation after DNA damage

  • These foci co-localize with γH2AX (marker of DNA double-strand breaks), indicating recruitment to damage sites

  • The temporal pattern of phosphorylation provides insights into the kinetics of DNA repair activation

• Distinguishing replication- vs. transcription-coupled damage responses:

  • At low-dose CPT, aphidicolin (a DNA polymerase inhibitor) completely abrogated S81-TDP1 phosphorylation, indicating replication-dependent activation

  • At high-dose CPT, both aphidicolin and DRB (transcription inhibitor) were required to block phosphorylation

  • pS81-TDP1 foci observed in non-replicating primary lymphocytes confirm transcription-dependent activation

The study demonstrated that TDP1–S81 phosphorylation promotes cell survival and DNA repair in response to CPT-induced double-strand breaks, suggesting a critical regulatory mechanism for TDP1 function in DNA damage response .

What is the relationship between TDP1 expression and sensitivity to anticancer treatments?

The relationship between TDP1 expression and anticancer drug sensitivity is complex and depends on multiple factors:

• TDP1/TOP1 ratio as a predictive biomarker:

  • TDP1 protein level alone does not significantly correlate with topotecan sensitivity

  • TDP1/TOP1 ratio correlates well with sensitivity in 8 out of 10 SCLC cell lines examined

  • This ratio may serve as a promising indicator for response to topoisomerase I inhibitors

  Cell Type	TDP1 Level	Drug Sensitivity	Notes
  SCLC lines	Variable (higher than other lung cancers)	Dependent on TDP1/TOP1 ratio	Remarkable variation in both TDP1 and TOP1 levels
  TDP1-/- cells	None	Hypersensitive to multiple agents	CPT, CNDAC, etoposide, MMS, H2O2, ionizing radiation

• Differential effects across drug classes:

  • TDP1-deficient cells show hypersensitivity to:

    • Topoisomerase I inhibitors (camptothecin, topotecan)

    • CNDAC (active metabolite of sapacitabine)

    • Other DNA-damaging agents including etoposide, MMS, H2O2, and ionizing radiation

  • Genetic background affects drug sensitivity patterns:

    • BRCA2-deficient cells: hypersensitive to CNDAC and CPT but not to AraC

    • PARP1-deficient cells: hypersensitive to CPT but not to CNDAC or AraC

• Mechanistic basis:

  • TDP1 deficiency causes:

    • Accumulation of TOP1-DNA complexes (TOP1cc)

    • Increased levels of both single-strand and double-strand breaks after treatment

    • Failure to repair 3'-phosphoglycolate at double-strand breaks

• Clinical implications:

  • TDP1 expression varies widely across cancer types in databases (CCLE, GDSC, NCI-60, TCGA)

  • Expression correlates with PARP1 expression, TDP1 gene copy number, and promoter methylation

  • TDP1 inhibitors under development could potentially synergize with topoisomerase I inhibitors

These findings suggest that assessing the TDP1/TOP1 ratio could help stratify patients for treatment with topoisomerase I inhibitors, and that TDP1 inhibition may represent a promising strategy for enhancing the efficacy of certain anticancer drugs.

How can TDP1 activity be measured in research contexts?

Multiple complementary approaches can be used to measure TDP1 activity in research settings:

• Biochemical enzyme activity assays:

  • Quantitative high-throughput screening (qHTS) methods using purified recombinant TDP1

  • Secondary screening using multiple loading gel-based assays with whole cell extracts

  • Critical considerations include:

    • Buffer composition (phosphate-based buffers can interfere with activity)

    • Substrate selection (oligonucleotides with 3'-phosphotyrosyl or other 3'-blocking lesions)

    • Inclusion of TDP1 knockout extracts as negative controls

• Cell-based activity assays:

  • Cell viability assays with TDP1-deficient cells complemented with human TDP1

  • Cells are treated with camptothecin with or without potential TDP1 inhibitors

  • Activity measured indirectly through survival after DNA damage

  • TDP1 activity correlates well with protein levels measured by antibodies in most cell lines

• Functional assays in cell extracts:

  • TDP1 activity in whole cell extracts can be measured and correlated with antibody-detected protein levels

  • Inhibitory TDP1 antisera can block activity in extracts, confirming specificity

  • TDP1 activity can be restored in deficient extracts by adding purified protein

• DNA damage measurement:

  • Alkaline comet assay to measure single-strand break accumulation

  • Neutral comet assay for double-strand breaks

  • Immunoblotting for TOP1cc using TOP1cc-specific antibodies

  • PAR (poly ADP-ribose) detection as an indirect measure of DNA damage and PARP1 activation

This multi-faceted approach provides comprehensive assessment of TDP1 activity in various experimental contexts, allowing researchers to correlate protein levels with functional outcomes in response to DNA damage and therapeutic interventions.

How do mutations in TDP1 affect its detection by antibodies?

Mutations in TDP1 can have varying effects on antibody detection, with important implications for studying diseases like SCAN1 (Spinocerebellar Ataxia with Axonal Neuropathy):

• Detection of SCAN1-associated H493R mutation:

  • The H493R mutation does not typically prevent antibody recognition in standard assays

  • Most antibodies targeting regions outside the mutation site can detect both wild-type and mutant proteins

  • Western blotting and immunofluorescence generally show similar signal patterns between wild-type and H493R mutant TDP1

• Functional versus expression differences:

  • While antibodies detect the mutant protein, they cannot distinguish functional deficits

  • SCAN1 mutant extracts show "residual activity" that can be inhibited by anti-TDP1 antiserum

  • The H493R mutation reduces but does not eliminate catalytic activity

  • The mutation stabilizes the TDP1 catalytic obligatory enzyme-DNA covalent complex

• Detection of TDP1-DNA adducts:

  • SCAN1 mutant TDP1 (H493R) accumulates enzyme-DNA intermediates

  • Specialized techniques may be needed to detect these covalent complexes:

    • DNA-protein crosslink isolation methods

    • TOP1cc-specific antibody approaches can be adapted for TDP1cc detection

• Methodological considerations:

  • Antibodies raised against different epitopes may show varying affinity for the mutant protein

  • Phospho-specific antibodies may reveal differences in post-translational modifications between wild-type and mutant TDP1

  • Functional assays are essential to complement antibody-based detection when studying mutant TDP1

• Validation approaches:

  • Compare signal intensity between wild-type and SCAN1 patient-derived cells

  • Use antibodies targeting different TDP1 epitopes to confirm consistent detection

  • Complement antibody detection with enzymatic activity assays

  • Verify specificity using TDP1 knockdown/knockout controls

These considerations highlight the importance of combining antibody-based detection with functional assays when studying TDP1 mutations, especially in the context of neurological disorders like SCAN1.

How should TDP1 antibody experiments be designed for immunohistochemistry?

For optimal TDP1 immunohistochemistry results, follow this comprehensive protocol:

• Tissue preparation and processing:

  • Fix tissues in 10% neutral buffered formalin

  • Process and embed in paraffin using standard protocols

  • Section tissues at 4-5 μm thickness

  • Mount sections on positively charged slides

• Antigen retrieval optimization:

  • Primary recommendation: TE buffer pH 9.0

  • Alternative method: Citrate buffer pH 6.0

  • Use heat-induced epitope retrieval (pressure cooker, microwave, or water bath)

  • Optimize time and temperature for specific tissues

• Antibody dilution and incubation:

  • Recommended dilution range: 1:50-1:500

  • Optimize concentration through titration experiments

  • Incubate at 4°C overnight or room temperature for 1-2 hours

  • Use appropriate antibody diluent to minimize background

• Detection and visualization:

  • Use a polymer-based detection system for enhanced sensitivity

  • Develop with DAB (3,3'-diaminobenzidine) chromogen

  • Counterstain with hematoxylin

  • Dehydrate and mount with permanent mounting medium

• Essential controls:

  • Positive tissue controls: Human ovary cancer tissue and human intrahepatic cholangiocarcinoma tissue

  • Negative controls: Primary antibody omission and isotype controls

  • TDP1 knockout/knockdown tissues where available

  • Competing peptide controls for polyclonal antibodies

• Scoring and interpretation:

  • TDP1 typically shows nuclear localization

  • Assess both staining intensity and percentage of positive cells

  • Document subcellular localization patterns

  • Quantify using digital image analysis for objective assessment

• Troubleshooting common issues:

  Issue	Possible Cause	Solution
  Weak/no signal	Insufficient antigen retrieval	Optimize pH, time, and temperature
  	Antibody concentration too low	Increase antibody concentration
  High background	Incomplete blocking	Extend blocking step, try different blockers
  	Antibody concentration too high	Decrease antibody concentration
  Cytoplasmic staining	Fixation artifacts	Adjust fixation time
  	True cytoplasmic localization	Validate with cell fractionation studies

Following these guidelines will help ensure specific and reproducible TDP1 detection in tissue samples for diagnostic and research applications.

What controls should be included when using TDP1 antibodies?

Proper controls are essential for validating TDP1 antibody specificity and ensuring reliable results across different applications:

• Positive controls:

  • Cell lines with confirmed TDP1 expression: MCF7 cells, HeLa cells

  • Tissues with known TDP1 expression: Human ovary cancer tissue, human intrahepatic cholangiocarcinoma tissue

  • Recombinant TDP1 protein (if available)

  • For phospho-specific antibodies: Cells treated with DNA damaging agents (CPT, ionizing radiation)

• Negative controls:

  • TDP1 knockout or knockdown cells/tissues

    • "Knock down of TDP1 by siRNA abrogated the pS81-TDP1 signal in CPT-treated cells"

    • TDP1-/- DT40 cells or human TDP1 KO cell lines (TSCER2, HCT116)

  • Primary antibody omission control

  • Isotype control antibodies (same species, isotype as TDP1 antibody)

• Specificity controls for phospho-specific antibodies:

  • Phosphatase treatment of samples should eliminate signal

  • Mutant constructs (e.g., S81A for pS81-TDP1 antibody)

  • "The specificity of the antibody for phosphorylated S81 was confirmed using ectopically expressed wild-type FLAG–TDP1 (FLAG–TDP1 WT) and mutated FLAG–TDP1 variants (S81A, S365A and S563A)"

• Application-specific controls:

  Application	Essential Controls
  Western blot	Molecular weight marker, loading control, knockout sample
  Immunoprecipitation	Input sample, IgG control, knockout sample
  Immunofluorescence	Primary antibody omission, knockout cells, blocking peptide
  Enzymatic assays	Pre-treatment with TDP1 inhibitory antibodies vs. pre-immune serum

• Validation across applications:

  • Confirm consistent results across multiple detection methods

  • Verify protein expression correlates with mRNA levels and enzymatic activity

  • Complementation studies: "Expression of human TDP1 (hTDP1) in the TDP1−/− cells enhanced cell viability"

Implementing these controls in TDP1 antibody experiments enhances data reliability and facilitates accurate interpretation of results, particularly in complex experimental contexts involving DNA damage responses and repair mechanisms.

How can TDP1 knockout/knockdown models be validated using antibodies?

Comprehensive validation of TDP1 knockout/knockdown models requires a multi-faceted approach utilizing antibodies:

• Genetic validation combined with protein detection:

  • Confirm gene disruption by genomic DNA sequencing of the targeted region

  • Verify complete protein loss by Western blotting in knockout models

  • For knockdown models, quantify the degree of protein reduction relative to control cells

  • "We knocked out TDP1 using CRISPR-Cas9" requires protein-level confirmation

• Multiple antibody approach:

  • Use antibodies targeting different epitopes of TDP1

  • Polyclonal antibodies recognizing multiple epitopes

  • Monoclonal antibodies targeting specific domains

  • Confirm consistent absence of signal across different antibodies

• Functional validation complementing antibody detection:

  • Express wild-type TDP1 in knockout cells to rescue phenotype

  • "Expression of human TDP1 (hTDP1) in the TDP1−/− cells enhanced cell viability"

  • Verify TDP1 re-expression by Western blot or immunofluorescence

  • This approach confirms that observed phenotypes are specifically due to TDP1 loss

• Phenotypic confirmation:

  • Demonstrate characteristic TDP1-deficiency phenotypes:

    • Hypersensitivity to camptothecin (CPT)

    • Increased accumulation of DNA breaks after CPT treatment

    • "TDP1−/− cells accumulated very high levels of SSBs measured by the alkaline comet assay and nuclear poly ADP-ribose"

    • Elevated levels of topoisomerase I-DNA complexes (TOP1cc)

This systematic approach ensures that TDP1 knockout/knockdown models accurately reflect TDP1 deficiency at both molecular and functional levels, providing reliable experimental systems for studying TDP1-dependent processes.

How can TDP1 antibodies be used in high-throughput screening for TDP1 inhibitors?

TDP1 antibodies play crucial roles in developing and validating high-throughput screening (HTS) assays for TDP1 inhibitors:

• Cell-based screening platform development:

  • TDP1 antibodies validate expression in engineered cell lines

  • "We developed a cell-based high-throughput screening method for TDP1 pathway inhibitors using a TDP1-deficient chicken DT40 cell line"

  • Confirm human TDP1 expression in complemented cells used for screening

  • Verify knockout status in parental cell lines

• Secondary validation of primary hits:

  • Western blotting to ensure compounds don't affect TDP1 protein levels

  • "We also developed a secondary screening method using a multiple loading gel-based assay where recombinant TDP1 is replaced by whole cell extract (WCE) from genetically engineered DT40 cells"

  • Immunodepletion experiments to confirm target specificity

  • "The high specificity of endogenous TDP1 in WCE allowed the evaluation of a large number of hits"

• Mechanism of action studies:

  • Immunofluorescence to track TDP1 localization after compound treatment

  • Co-immunoprecipitation to determine if compounds disrupt protein-protein interactions

  • Western blotting to assess effects on post-translational modifications

  • Antibody-based activity assays to directly measure enzymatic inhibition

• Critical considerations:

  • Buffer optimization: "The importance of buffer conditions for testing TDP1, and most notably the possible interference of phosphate-based buffers"

  • Antibody specificity: Validate with knockout controls

  • Multiple detection methods: Combine antibody-based and activity-based assays

  • "The increased stringency of the WCE assay eliminated a large fraction of the initial hits collected from the qHTS"

This integrated approach leveraging TDP1 antibodies facilitates the discovery and characterization of specific TDP1 inhibitors, which could potentially be developed as adjuvants to enhance the efficacy of topoisomerase I inhibitors in cancer treatment.

How should variations in TDP1/TOP1 ratio be interpreted for predicting drug sensitivity?

The TDP1/TOP1 ratio provides valuable insights into potential drug sensitivity patterns, particularly for topoisomerase I inhibitors:

• Correlation with drug response:

  • "TDP1 protein level alone does not correlate with topotecan sensitivity, TDP1/TOP1 ratio correlates well with sensitivity in 8 out of 10 cell lines examined"

  • Higher TDP1/TOP1 ratios generally associate with decreased sensitivity to TOP1 inhibitors

  • This relationship reflects the balance between damage induction (TOP1) and repair capacity (TDP1)

• Standardized measurement approach:

  • Quantify both TDP1 and TOP1 via Western blotting with appropriate controls

  • Normalize signals to loading controls (β-actin, GAPDH)

  • Calculate TDP1/TOP1 ratio using normalized values

  • Compare across cell lines with known drug response profiles

• Interpretation framework:

  TDP1/TOP1 Ratio	Expected Drug Response	Mechanistic Basis
  High	Resistance to TOP1 inhibitors	Enhanced repair capacity relative to damage induction
  Low	Sensitivity to TOP1 inhibitors	Limited repair capacity relative to damage level
  Variable	Inconsistent response	Additional repair pathways may compensate

• Integration with other markers:

  • Consider PARP1 status: "Cells lacking PARP1 were only hypersensitive to CPT but not to CNDAC or AraC"

  • Evaluate BRCA1/2 status: "Inactivation of BRCA2 renders cells hypersensitive to CNDAC and CPT but not to AraC"

  • TDP1 expression correlates with "PARP1 expression, TDP1 gene copy number and promoter methylation"

• Clinical application potential:

  • "This study provides the first cellular analyses of TDP1 and TOP1 in SCLC and suggests the potential utility of TDP1/TOP1 ratio to assess the response of SCLC to topotecan"

  • Could serve as a predictive biomarker for patient stratification

  • Might guide combination therapy selection based on repair pathway status

• Limitations and considerations:

  • Two out of ten cell lines did not follow the correlation in the study

  • Other DNA repair pathways may influence response independent of TDP1/TOP1 ratio

  • Tumor heterogeneity may complicate clinical applications

  • Functional validation through enzymatic assays provides additional confidence

This interpretation framework helps researchers translate TDP1/TOP1 ratio measurements into meaningful predictions about drug sensitivity, potentially guiding both preclinical research and clinical applications in cancer treatment.